Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Greenwich LifeSciences, Inc. (GLSI)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative [+] | 0.4 | 0.4 | 0.7 | 0.1 | 0.3 | 0.3 | 0.2 | 0.2 |
| General and administrative | 0.4 | 0.4 | 0.7 | 0.1 | 0.3 | 0.3 | 0.2 | 0.2 |
| Research and development | 1.4 | 2.5 | 1.7 | 0.6 | 1.7 | 2.1 | 0.7 | 0.6 |
| EBITA | -1.7 | -2.9 | -2.4 | -0.8 | -2.0 | -2.4 | -0.9 | -0.8 |
| Amortization of intangibles | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -1.7 | -2.9 | -2.4 | -0.8 | -2.0 | -2.4 | -0.9 | -0.8 |
| EBIT growth | 126.0% | 21.8% | 175.0% | 2.6% | 231.2% | 106.4% | 237.4% | 258.1% |
| Interest income | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -1.6 | -2.8 | -2.3 | -0.7 | -2.0 | -2.4 | -0.9 | -0.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -1.6 | -2.8 | -2.3 | -0.7 | -2.0 | -2.4 | -0.9 | -0.7 |
| |
| Basic EPS [+] | ($0.13) | ($0.22) | ($0.18) | ($0.06) | ($0.15) | ($0.18) | ($0.07) | ($0.06) |
| Growth | 119.5% | 20.3% | 157.1% | -3.8% | 200.0% | 49.2% | 139.5% | 144.9% |
| Diluted EPS [+] | ($0.13) | ($0.22) | ($0.18) | ($0.06) | ($0.15) | ($0.18) | ($0.07) | ($0.06) |
| Growth | 119.5% | 20.3% | 157.1% | -3.8% | 200.0% | 49.2% | 139.5% | 144.9% |
| |
| Shares outstanding (basic) [+] | 12.8 | 12.8 | 12.9 | 12.9 | 13.1 | 13.1 | 12.3 | 12.5 |
| Growth | -0.6% | -1.8% | 4.5% | 3.4% | 10.0% | 37.5% | 40.3% | 45.5% |
| Shares outstanding (diluted) [+] | 12.8 | 12.8 | 12.9 | 12.9 | 13.1 | 13.1 | 12.3 | 12.5 |
| Growth | -0.6% | -1.8% | 4.5% | 3.4% | 10.0% | 37.5% | 40.3% | 45.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|